Is There a Recall on Gabapentin? What You Need to Know

Gabapentin has not been subject to a broad, nationwide recall by the U.S. Food and Drug Administration. The drug remains approved and widely prescribed for epilepsy, postherpetic neuralgia, and restless legs syndrome. That said, individual manufacturers have occasionally issued limited recalls of specific gabapentin batches due to manufacturing defects or labeling errors, and the FDA has added significant safety warnings to the drug in recent years. If you searched for a gabapentin recall, there is a good chance you encountered news about one of these events and want to know whether your medication is affected or whether the drug itself has been deemed unsafe.

Why People Think There Might Be a Recall

Confusion about gabapentin recalls usually stems from one of two things. First, the FDA’s recall database does periodically list gabapentin products from specific manufacturers. These are narrow actions: a particular lot of capsules from one company pulled because of, say, incorrect labeling or a failed dissolution test. They do not mean the drug as a class is dangerous or withdrawn. Second, the FDA issued a high-profile safety communication in December 2019 warning about serious breathing problems associated with gabapentin and its close relative pregabalin, especially when used alongside opioids or other central nervous system depressants, or in patients with respiratory risk factors like chronic obstructive pulmonary disease.¹ That warning made national news and, for many patients, felt like the first sign that something was seriously wrong with a medication they had been taking for years.

To check whether your specific bottle is part of a limited recall, search the FDA’s recall database by the manufacturer name or lot number printed on your label. If your product does not appear, it has not been recalled. If it does, your pharmacist can swap it for an unaffected lot at no extra cost.

The FDA’s 2019 Breathing Warning

The December 2019 safety alert was a turning point in how regulators talked about gabapentin. The FDA required new warnings on the labels of all gabapentinoid products (gabapentin and pregabalin) stating that the drugs can cause respiratory depression. The agency based this on case reports from its adverse event database and from published medical literature documenting slowed or dangerously shallow breathing, sometimes leading to death.

The risk is highest in certain groups. People using gabapentin together with opioid painkillers face the most danger, but the FDA also flagged older adults, people with lung disease, and anyone taking other sedating medications. The concern is that gabapentin may amplify the respiratory-depressing effects of these other drugs, creating a compounding problem that neither drug alone would cause at its prescribed dose.¹ If you take gabapentin and notice unusual drowsiness, confusion, or any difficulty breathing, treat it as urgent.

The Opioid Combination Problem

The breathing warning does not exist in a vacuum. A large body of research has now quantified just how dangerous the gabapentin-plus-opioid combination can be. A population-based study spanning more than 16 years found that roughly 8 percent of patients receiving opioids were also prescribed gabapentin. That co-prescription was associated with about a 50 percent increase in the risk of dying from opioid-related causes. At very high doses of gabapentin, the risk nearly doubled.² The likely mechanism involves both a direct additive effect on breathing suppression and a pharmacokinetic interaction in which opioids increase gabapentin blood levels.

Additional research has looked at this risk in different clinical settings. In chronic pain and perioperative contexts, the increased odds of respiratory depression or opioid-related death with gabapentinoid co-exposure have been estimated at around 1.3 times higher. In opioid maintenance treatment programs, where patients are on drugs like methadone or buprenorphine, the hazard was substantially steeper. Experimental studies have also shown that even a single dose of a gabapentinoid can reverse the tolerance to respiratory depression that long-term opioid users develop, meaning the combination may catch experienced opioid users off guard.³

This does not mean you must immediately stop one or the other if your doctor has prescribed both. But you should have a frank conversation about whether the combination is still necessary, whether doses can be lowered, and what warning signs to watch for.

Why Some States Now Treat Gabapentin as a Controlled Substance

Gabapentin is not classified as a controlled substance at the federal level. The DEA has not scheduled it. But a growing number of states have taken matters into their own hands. Kentucky became the first state to classify gabapentin as a Schedule V controlled substance in July 2017, and West Virginia followed in June 2018.⁴ Several other states have since added gabapentin to their prescription drug monitoring programs or imposed similar controls.⁵

The motivation was rising evidence of gabapentin misuse, particularly alongside opioids. In some communities, gabapentin had become a drug of abuse in its own right or a way to intensify the effects of other substances. West Virginia specifically evaluated whether its scheduling change affected fatal overdose rates involving gabapentin.⁶

For you as a patient, the practical effect depends on where you live. In states with Schedule V classification, your gabapentin prescription may have refill limits, require a new prescription rather than phone-in renewals, and show up on your state’s prescription monitoring database. If you move states or travel frequently, the rules can change, so check with your pharmacist about local requirements.

Off-Label Use and the Evidence Gap

One reason gabapentin generates so much discussion is that a huge share of its prescriptions are for conditions it was never formally approved to treat. A review of prescribing practices at a large medical center found that the top indications included neuropathic pain (which is approved), but also musculoskeletal pain, anxiety, and headache, many of which lack strong supporting evidence. About 29 percent of prescriptions in that sample were backed by conflicting or insufficient evidence.⁷

A broader look at the off-label landscape paints a similar picture. Reviews of gabapentin for conditions like migraine, fibromyalgia, mental illness, and substance dependence have found modest to no effect on the outcomes that matter, and much of the optimism around these uses has been driven by small, uncontrolled studies rather than rigorous trials.⁸ In psychiatry, the evidence is mixed. A systematic review found that gabapentin may help with certain anxiety conditions and with alcohol craving and withdrawal, but there is no clear evidence for its use in depression, PTSD prevention, OCD, or most other psychiatric applications.⁹

None of this means gabapentin is useless off-label for everyone. But it does mean that if you were prescribed gabapentin for something other than epilepsy, postherpetic neuralgia, or restless legs, the evidence behind that choice may be thinner than you assume. It is worth asking your prescriber what the supporting evidence looks like for your specific condition and whether alternatives with stronger data exist.

What Happens If You Stop Gabapentin Suddenly

Whether or not your particular batch has been recalled, the question of stopping gabapentin is relevant to anyone taking it. Gabapentin should not be discontinued abruptly. Withdrawal symptoms can appear even when a patient has been tapered, not just when the drug is stopped cold turkey. In one documented case, a patient who was tapered off gabapentin developed moderate symptoms within a day of the final dose: upper respiratory symptoms and general physical discomfort that gradually worsened over about ten days, at which point she developed severe mental status changes, chest pain, and high blood pressure. Restarting gabapentin brought her back to baseline within a day or two.¹⁰

This is not a rare anecdote pulled from thin air. Withdrawal from gabapentin is well-recognized, and it can include anxiety, insomnia, nausea, sweating, and in severe cases, seizures, even in patients who were not taking gabapentin for epilepsy. If you learn that your specific product has been recalled and need to switch to a different manufacturer’s version, your pharmacist can usually do that seamlessly. But if for any reason you cannot get a replacement and are considering just stopping, talk to your doctor first. A supervised taper is always safer than an abrupt stop.

How Gabapentin Actually Works in the Body

Despite its name, gabapentin does not work through the GABA system the way many people assume. The drug was originally designed to mimic the neurotransmitter GABA, but research has shown that its actual target is a specific part of voltage-gated calcium channels in nerve cells, known as the alpha-2-delta-1 subunit. By binding to this subunit, gabapentin disrupts the trafficking of calcium channels to the cell surface, which in turn dials down the release of excitatory neurotransmitters that carry pain and seizure signals.¹¹ Genetic studies in mice have confirmed that if you knock out or mutate this specific binding site, gabapentin loses its pain-relieving effects entirely.¹²

An interesting wrinkle is that this effect is not immediate. Gabapentin appears to work chronically rather than acutely, meaning its pain-reducing and anti-seizure benefits build over time as more calcium channels are prevented from reaching the nerve cell surface.¹¹ This also explains why it needs to be tapered rather than stopped abruptly: the nervous system has adapted to the drug’s steady presence, and removing it suddenly leaves those pathways unregulated.

Kidney Function and Gabapentin Dosing

Gabapentin is unusual among common medications in that it is eliminated almost entirely through the kidneys, with no significant liver metabolism. This means that anyone with reduced kidney function will accumulate higher blood levels of the drug, experience a longer time before each dose clears, and face a greater risk of side effects at standard doses.¹³ Dosing adjustments based on kidney function are not optional; they are essential.

This matters more than you might think because kidney function declines naturally with age, and gabapentin is frequently prescribed to older adults for nerve pain. If you are over 65, have diabetes, or have any history of kidney problems, your dose should be calculated based on a measure of how well your kidneys are filtering. Many patients end up on doses that were appropriate when they started the drug but become too high as their kidney function gradually declines. If you have been on gabapentin for years and no one has rechecked your kidney function recently, bring it up at your next appointment.

Gabapentin in the Supply Chain

Gabapentin is one of the most commonly dispensed oral medications in the United States, which means it sits at the center of a complex generic supply chain. An analysis of U.S. government databases confirmed that gabapentin and pregabalin are the most common oral anti-seizure medications on the market.¹⁴ Dozens of manufacturers produce generic gabapentin in capsule, tablet, and liquid forms, and the active ingredient is sourced from facilities around the world.

This high volume generally means good availability, but it also means that when a quality problem is detected at one manufacturer, the recall affects only that manufacturer’s lots while the drug remains freely available from other suppliers. Your pharmacy will typically substitute a different manufacturer’s product without any lapse in your supply. If you do experience a gap, ask your pharmacist whether they can order from an alternate distributor or whether a nearby pharmacy has stock.

A Warning for Dog Owners

Gabapentin is increasingly prescribed by veterinarians for pain and anxiety in pets, and this creates a specific hazard that has nothing to do with human recalls. The commercially available liquid formulation of gabapentin contains xylitol at a concentration of 300 mg per milliliter. Xylitol is extremely toxic to dogs, even in small amounts, potentially causing life-threatening drops in blood sugar and liver failure. For this reason, veterinary guidelines recommend that dogs receive gabapentin only in tablet or capsule form, never the liquid.¹⁵

If your vet prescribes liquid gabapentin for your dog, ask specifically whether the formulation contains xylitol. Compounding pharmacies can prepare xylitol-free liquid versions when a liquid is necessary, for instance for very small dogs who cannot swallow capsules. Cats are not affected by xylitol in the same way, so the liquid form is generally considered safe for feline patients, but always confirm with your veterinarian.

Counterfeit and Online-Sourced Gabapentin

As gabapentin has come under tighter prescribing controls in some states, a secondary concern has emerged: people obtaining gabapentin outside the regulated pharmacy system. Research into internet-sourced controlled drugs in the UK found that medications purchased online frequently arrive in poor condition, with inconsistent dosing or no active ingredient at all. In one documented case, a buyer sent pills purchased online to a testing service, which confirmed they contained no active substance whatsoever. The same buyer described wide variation between pills even within a single batch.¹⁶

While that study focused broadly on sedatives and GABA-related drugs rather than gabapentin alone, the principle applies directly. If you obtain gabapentin from an unregulated online source, you have no guarantee that the pills contain the correct dose, the correct drug, or any active ingredient at all. The irony is that patients worried about the safety of their FDA-regulated gabapentin may face far greater danger from unregulated alternatives. If cost or access is a barrier to filling your prescription through a licensed pharmacy, patient assistance programs and generic pricing (gabapentin is inexpensive as generics go) are almost always safer routes.

1
PubMed Central. Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?
2
PubMed Central. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study
3
PubMed. Non-opioid antinociceptive drugs: risk of respiratory depression and death related to concomitant use of gabapentinoids in addition to opioids
4
PubMed Central. Decreased Gabapentin Prescription Fills Among Medicaid Enrollees Following State-Level Schedule V Controlled Substance Classification in Kentucky and West Virginia
5
PubMed. Gabapentin controlled substance status
6
PubMed Central. Impact of schedule V controlled substance classification of gabapentin on adult gabapentin-involved overdose rates, West Virginia, 2016-2019: A controlled time series analysis
7
Elsevier / ScienceDirect (Mayo Clinic Proceedings: Innovations, Quality & Outcomes). Gabapentinoid Prescribing Practices at a Large Academic Medical Center
8
PubMed Central. Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?
9
PubMed Central. Gabapentin Therapy in Psychiatric Disorders: A Systematic Review
10
PubMed. Gabapentin withdrawal syndrome in the presence of a taper
11
PubMed Central. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin
12
PubMed Central. Mechanisms of the gabapentinoids and α2δ‐1 calcium channel subunit in neuropathic pain
13
PubMed. Pharmacokinetics of gabapentin in subjects with various degrees of renal function
14
PubMed. US Generic Antiseizure Medication Supply Chain: Observations from Analysis of US Government Databases
15
The Veterinary Clinics of North America: Small Animal Practice. Management of Epilepsy in Dogs and Cats
16
Emerging Trends in Drugs, Addictions, and Health. Internet sourcing and unsafe use of controlled drugs (opioids, sedatives and GABA drugs) in the UK: An in depth case study of consumer dynamics during COVID-19